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surveillance data collection. Such are defined as an aircraft without a human pilot 
on board, operated either autonomously by computer or under remote control by 
a human pilot. Methods: We performed a targeted literature search for medi-
cal applications of UAS and rank-ordered strengths and weaknesses according to 
emerging applications and corresponding difficulty, feasibility and cost. Results: 
Based on secondary sources, we report conceptual factors that can contribute to the 
practicality and efficiency of UAS in emergency medical situations. These were 1) 
frequency of occurrence, 2) time-sensitivity of occurrence, 3) rurality and complex 
terrain, 4) financial impact and 5) cultural acceptance. The results of our matrix 
point to a gradation of accepted uses for UAS with the variance in geographical 
location and urgency directly relating to an increase in operation costs. It is well 
known that natural disasters are increasing in frequency and intensity. Salient 
platforms for using UAS in medical delivery would be in the areas of natural and 
combative disaster relief. During these occurrences the use of UAS to aid in the 
medical relief could be a great asset. ConClusion: Our model illustrates how Big 
Data can be leveraged to improve ongoing quality and efficiency of UAS-delivered 
medical supplies, reduce time for delivery of supplies during times of natural dis-
asters, and thus eschew our reliance on manned aircraft to assist in critical and 
non-critical medical operations.
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The epidemiological and economic methods applied to health technologies evalu-
ations had a significant development in the last two decades. The need to balance 
the incorporation of new technologies in health care and limited financial resources 
promoted the construction and application of instruments supporting the decision 
making of health technology. The requirement Budget Impact Analysis formally 
stated in Law 12.401/2011 establishing the incorporation process technologies in 
SUS. In this context, in 2010/2011, the National Agency of Sanitary Surveillance 
(ANVISA) and DECIT, in partnership Institute for Health Technology Assessment 
(IATS) for drawing up of this guideline. In the first stage of development were 
used international recommendations of Canada, Australia, the UK and Poland, 
the recommendations of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the methods used in studies of budgetary impact 
that had already been published. Afterwards, drafted a preliminary version of the 
Guideline and a standard tool - Excel worksheets - to estimate the uptake of mon-
etary resources required for adoption of new technologies. Revisions were carried 
out by technicians DECIT and health agencies, and the proposal was submitted to 
the Working Group on Development of Methodology REBRATS, composed of experts 
and academic researchers from several Brazilian states. Were also carried out work-
shops for the application of spreadsheets. In 2012, the first edition of the Guidelines 
was published two thousand copies in Portuguese in order to provide best practice 
recommendations for studies of budget impact.
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Mixed methods are fast becoming the go-to methodology for the development and 
validation of clinical outcome assessments (COAs). Although mixed methods have 
become popularized for COA development, most of this attention has focussed on 
Rasch measurement theory (RMT). However, the potential utility of mixed methods 
in COA development goes beyond RMT. There is a well-established literature base 
exploring the use of mixed data collection and crossover analyses in social research 
and many of these approaches can be readily applied to COA development. Thus a 
toolkit of methods is proposed which can be pragmatically selected to support the 
development of interpretable and purposeful COAs. Further integration of qualita-
tive and quantitative data throughout the COA development process can serve to 
continually test the evolving hypothesis of the measurement construct and aid 
in evidence triangulation. Data can be transformed to create new data through 
‘quantitizing’ qualitative data and ‘qualitizing’ quantitative data. Qualitative data 
collected during concept elicitation can be converted into binary code allowing 
development of inter- and intra-respondent matrices to explore the frequency 
and intensity of concepts. These data can be subjected to factor, correlational and 
regression analyses to explore the hierarchical structure and inter-relationships of 
qualitatively-derived themes and variables. Concept mapping techniques also allow 
the translation of qualitative data into pictorial form to show “clusters” of, or inter-
relationships between, concepts. This collaborative approach involves stakeholders 
as partners in the research to generate, sort and rate items into conceptual models 
using statistical analyses. There are exciting opportunities to build upon existing 
practice and advance mixed research approaches in the field of COA development. 
Integrating mixed data collection and crossover analyses can enhance the interpret-
ability and purposefulness of COAs ensuring they are developed with an evolving 
hypothesis and fit for purpose. The application of such methods for regulatory COA 
development requires further exploration.
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guidelines used in clinical research: The Cochrane Reviewer’s Handbook and a guide-
line prepared by the The Australian National Health and Medical Research Council. 
The aim of the guideline was to introduce the main concepts through a language 
that is more simple and accessible to health care professionals, familiar or not with 
the methodology of systematic reviews and meta-analyses. This guideline covers 
the three phases of a SR: planning, production and reporting of the SR. It does not 
take into account the impact of the type of question in the review process and does 
not exhaust all the mechanisms necessary in order to understand and perform a 
meta-analysis. It also presents the detailing of some fundamental concepts needed 
to conduct the systematic review in the form of appendices. In 2011, it was given the 
first version of the guideline. DECIT was responsible for the review and publishing 
of the final document. In 2012, the first issue of the guideline was published. The 
importance of the guideline is to orient and standardize the preparation and pro-
duction of a quality SR, mainly due to the gap that exists in the national literature.
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The advent of ePROs and direct-to-patient reporting has enabled patients participat-
ing in registries to report their symptom or treatment experiences between physi-
cian visits, with minimal patient burden. These independent reporting approaches 
are often used to support patient retention over long follow-up periods, and/or to 
collect patient-reported data outside of typical physician visit schedules. When a 
patient completes PROs independent of a physician’s presence (i.e., not completed 
at the physician’s office and not entered by the registry site), the treating physician 
may not be aware of the patient’s responses and may need to either proactively 
ask for this information or wait to obtain this information at the end of the study. 
The move toward independent reporting of PRO data introduces several competing 
concerns. First, physician knowledge of the PRO responses could potentially alter 
the naturalistic follow-up in an observational study, if, for example, the physician’s 
knowledge of the PRO response prompts him/her to alter the patient’s treatment. 
As a result, patient reporting independence may be preferred from a research purity 
perspective. However, any PRO response that may be a safety signal would carry 
ethical considerations; in such a case, reporting independence would not be pre-
ferred. If patient care is always paramount to the benefits of research, then it could 
be argued that the optimization of patient care is only possible when the physician 
has all available patient information (e.g., PROs) at his/her disposal, in as close to 
real-time as possible. In addition, some research indicates that patients are more 
likely to complete PROs when their physician is aware of and using the PRO data to 
inform treatment decisions. Further discussion will focus on sponsor and researcher 
responsibilities for funneling observed data on a patient’s experience back to the 
treating physician, drawing on examples from the literature and registry protocols.
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PuRPose: To describe the most effective approaches to achieving a real-world 
study data sample that is representative of the target population. desCRiPtion: 
Considerable attention is paid to the design and analysis of outcomes research 
studies to address internal validity by minimizing bias and confounding. However, 
too often, study sample populations are simply assumed to be representative of 
the study populations from which they are drawn, or are assessed for their repre-
sentativeness only after the study has been conducted. Ideally, sample estimates 
should be as close as possible to their population value in order to make inferences 
about that study population. Practical implementation of measures to avoid selec-
tion bias and ensure a robust sampling procedure can be problematic. Challenges 
include, willingness of sites and patients to participate in research (convenience 
sampling), and management of site and patient drop-out after the study has begun. 
While many database studies and patient registries carry very large sample sizes 
and therefore begin to approximate the target population simply by means of 
sheer size, smaller studies may need to take steps, through stratified sampling 
and enrollment caps, to ensure that the study sample is reflective of the target 
population. These stratification variables may be at the site level (e.g., physician 
specialty, geography), the patient level (age, gender, ethnicity, disease duration) or 
both. Temporal issues may also be problematic where studies performed in the past 
may not reflect rapid changes impacting today’s target population. Following a brief 
overview of the design and analysis considerations, this presentation will focus on 
case examples, drawn from different organizations, of approaches to achieving a 
representative sample, highlighting some of the challenges intrinsic to real-world 
research. Best practice recommendations will be provided to guide researchers on 
the most effective approaches, including the use of reference populations within 
specific countries.
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objeCtive: We propose a paradigm and ranking system for potential medical 
applications of unmanned aircraft systems (collectively UAS). Over the past three 
decades, UAS have become a vital component to our armed forces, used notably 
for combat but also commonly used for work in intelligence, reconnaissance and 
